|
Market Closed -
NYSE
04:30:00 14/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 10.40 USD | +1.96% |
|
-0.76% | -29.49% |
| 07-30 | Daxor Launches Blood Testing Lab in Eastern Kansis | MT |
| 07-30 | Daxor Corporation Initiates Outpatient Blood Volume Analysis Program in Kansas | CI |
| Market Cap | 60.6M 52.41M 49.24M 44.78M 84.08M 5.78B 85.59M 577M 225M 2.9B 227M 223M 9.65B | P/E 2026 * |
-49.5x | P/E 2027 * | -347x |
|---|---|---|---|---|---|
| Enterprise Value | 60.6M 52.41M 49.24M 44.78M 84.08M 5.78B 85.59M 577M 225M 2.9B 227M 223M 9.65B | EV / Sales 2026 * |
5.09x | EV / Sales 2027 * | 2.91x |
| Free-Float |
46.74% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Daxor Corporation
| 1 week | 10.05 | 10.45 | |
| 1 month | 10.05 | 11.97 | |
| 3 years | 6.55 | 14.76 | |
| 5 years | 6.55 | 14.76 | |
| 10 years | 3.4 | 24.08 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2013 | |
Robert Michel
DFI | Director of Finance/CFO | 69 | 28/09/2018 |
John Jefferies
CTO | Chief Tech/Sci/R&D Officer | - | 05/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
James Lombard
BRD | Director/Board Member | 91 | 01/01/1989 |
| Chairman | 56 | 14/02/2017 | |
Edward Feuer
BRD | Director/Board Member | 70 | 22/06/2016 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.96% | -0.76% | - | - | 60.6M | ||
| +0.70% | +1.10% | +29.60% | +124.07% | 15.76B | ||
| +0.52% | +1.25% | +63.41% | +172.00% | 13.32B | ||
| +1.81% | +0.66% | -6.24% | +32.50% | 9.3B | ||
| +0.77% | +2.18% | +43.69% | +151.58% | 8.23B | ||
| -0.76% | -2.05% | -17.97% | -16.97% | 7.27B | ||
| -0.04% | -0.07% | +17.17% | +54.89% | 6.68B | ||
| -0.26% | -0.39% | +9.74% | +27.67% | 4.79B | ||
| +0.64% | +1.20% | +11.81% | +9.15% | 4.14B | ||
| +0.20% | +2.57% | - | - | 4.03B | ||
| Average | +0.40% | +1.28% | +18.90% | +69.36% | 8.17B | |
| Weighted average by Cap. | +0.51% | +1.69% | +24.36% | +89.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11.9M 10.29M 9.67M 8.79M 16.51M 1.14B 16.81M 113M 44.27M 569M 44.66M 43.71M 1.9B | 20.8M 17.99M 16.9M 15.37M 28.86M 1.98B 29.37M 198M 77.38M 995M 78.06M 76.39M 3.31B |
| Net income | -1.2M -1.04M -975K -887K -1.66M -114M -1.69M -11.42M -4.46M -57.4M -4.5M -4.41M -191M | -200K -173K -162K -148K -277K -19.08M -282K -1.9M -744K -9.57M -751K -735K -31.86M |
| Net Debt | - | - |
Employees
-
Sector
Closed End Funds
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/08/26 | US$0.000000 | -100.00% | 187 |
| 13/08/26 | US$10.40 | +1.96% | 530 |
| 12/08/26 | US$10.20 | -0.39% | 2,558 |
| 11/08/26 | US$10.24 | -2.01% | 4,069 |
| 10/08/26 | US$10.45 | +3.36% | 931 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.40USD
Average target price
22.50USD
Spread / Average Target
+116.35%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- DXR Stock
- DXR Stock
Select your edition
All financial news and data tailored to specific country editions

















